US 12,168,034 B2
Inhibition of TREM receptor signaling with peptide variants
Alexander B. Sigalov, Worcester, MA (US)
Assigned to SIGNABLOK, INC., Shrewsbury, MA (US)
Filed by SignaBlok, Inc., Shrewsbury, MA (US)
Filed on Apr. 4, 2023, as Appl. No. 18/130,764.
Application 18/130,764 is a continuation of application No. 15/962,589, filed on Apr. 25, 2018, granted, now 11,638,739.
Application 15/962,589 is a continuation of application No. 13/941,445, filed on Jul. 12, 2013, granted, now 9,981,004, issued on May 29, 2018.
Application 13/941,445 is a continuation of application No. 13/501,992, granted, now 8,513,185, issued on Aug. 20, 2013, previously published as PCT/US2010/052566, filed on Oct. 13, 2010.
Claims priority of provisional application 61/251,283, filed on Oct. 13, 2009.
Prior Publication US 2023/0364179 A1, Nov. 16, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/03 (2006.01); C07K 7/08 (2006.01); C07K 14/00 (2006.01); C07K 14/70 (2006.01); C07K 14/705 (2006.01)
CPC A61K 38/03 (2013.01) [C07K 7/08 (2013.01); C07K 14/001 (2013.01); C07K 14/70503 (2013.01); Y02A 50/30 (2018.01)] 20 Claims
 
1. A peptide inhibitor comprising an amino acid sequence consisting of
X1-X2-X3-G-F-L-S-K-S-L-V-R-V-X4-X5 (SEQ ID NO: 2), wherein X1 consists of G, C or nothing; and X2, X3, X4, and X5 consist of K, R, or nothing.